Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Monday September 29 9:06 AM EDT
These and other results will be reported by clinical investigators at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy meeting being held in Toronto, Ontario, Canada, September 28 - October 1, the company said.
Clinical investigators will present long-term virological and immunological results from Study 511, a trial evaluating VIRACEPT taken in combination with Retrovir and Epivir in 297 patients whose mean viral load was 153,044 viral copies per milliliter of plasma. Viral load refers to the amount of HIV in the blood.
After 12 months of treatment, the mean reduction in viral load for those taking 750mg of VIRACEPT three times daily was greater than 99 percent using the Roche Holding (ROCZG.S) AMPLICOR HIV Monitor, the company said.
970929
RE970916
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .